Ghada El-Hajj Fuleihan, M.P.H.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Vitamin D | 28 | 2024 | 3303 | 3.970 |
Why?
|
Hypercalcemia | 6 | 2023 | 423 | 3.580 |
Why?
|
Vitamin D Deficiency | 16 | 2024 | 1384 | 3.460 |
Why?
|
Bone Density | 37 | 2024 | 3549 | 3.230 |
Why?
|
Bone Density Conservation Agents | 7 | 2023 | 795 | 2.550 |
Why?
|
Vitamins | 11 | 2024 | 1635 | 2.360 |
Why?
|
Osteoporosis | 16 | 2023 | 1603 | 2.310 |
Why?
|
Cholecalciferol | 8 | 2022 | 552 | 2.140 |
Why?
|
Parathyroid Hormone | 9 | 2022 | 1802 | 2.070 |
Why?
|
Osteoporotic Fractures | 8 | 2020 | 411 | 1.760 |
Why?
|
Absorptiometry, Photon | 18 | 2022 | 1736 | 1.470 |
Why?
|
Dietary Supplements | 12 | 2024 | 3405 | 1.390 |
Why?
|
Hyperparathyroidism, Primary | 2 | 2022 | 163 | 1.310 |
Why?
|
Osteoporosis, Postmenopausal | 6 | 2021 | 396 | 1.310 |
Why?
|
Parathyroidectomy | 4 | 2022 | 242 | 1.200 |
Why?
|
Lebanon | 13 | 2024 | 245 | 1.190 |
Why?
|
Sarcopenia | 2 | 2022 | 372 | 1.110 |
Why?
|
Hip Fractures | 8 | 2019 | 988 | 1.000 |
Why?
|
Fractures, Bone | 8 | 2024 | 2045 | 0.910 |
Why?
|
Hyperparathyroidism | 3 | 2012 | 337 | 0.890 |
Why?
|
Musculoskeletal Development | 2 | 2016 | 14 | 0.800 |
Why?
|
Diphosphonates | 6 | 2023 | 636 | 0.780 |
Why?
|
Bariatric Surgery | 2 | 2024 | 991 | 0.760 |
Why?
|
Puberty | 4 | 2016 | 501 | 0.740 |
Why?
|
Bone Diseases, Metabolic | 4 | 2011 | 409 | 0.700 |
Why?
|
Paraneoplastic Syndromes | 1 | 2021 | 155 | 0.690 |
Why?
|
Overweight | 4 | 2021 | 2412 | 0.680 |
Why?
|
Body Composition | 7 | 2016 | 2421 | 0.610 |
Why?
|
Aromatase Inhibitors | 1 | 2021 | 511 | 0.590 |
Why?
|
Bone Remodeling | 6 | 2021 | 581 | 0.580 |
Why?
|
Pelvic Bones | 2 | 2017 | 270 | 0.580 |
Why?
|
Calcium | 7 | 2022 | 5726 | 0.570 |
Why?
|
Phosphorus | 2 | 2016 | 336 | 0.560 |
Why?
|
Spinal Fractures | 6 | 2016 | 705 | 0.540 |
Why?
|
Alkaline Phosphatase | 3 | 2016 | 866 | 0.540 |
Why?
|
Hypocalcemia | 2 | 2020 | 199 | 0.520 |
Why?
|
Osteocalcin | 1 | 2016 | 274 | 0.520 |
Why?
|
Estrogen Replacement Therapy | 2 | 2015 | 1208 | 0.500 |
Why?
|
Obesity | 8 | 2024 | 12918 | 0.490 |
Why?
|
Neoplasms | 5 | 2023 | 22083 | 0.490 |
Why?
|
Femur Head | 1 | 2016 | 297 | 0.460 |
Why?
|
Monitoring, Intraoperative | 1 | 2020 | 941 | 0.460 |
Why?
|
Anticonvulsants | 3 | 2023 | 1903 | 0.420 |
Why?
|
Humans | 81 | 2024 | 760437 | 0.380 |
Why?
|
Hip Joint | 3 | 2013 | 1013 | 0.370 |
Why?
|
Double-Blind Method | 8 | 2022 | 12320 | 0.370 |
Why?
|
Seizures | 1 | 2023 | 2956 | 0.360 |
Why?
|
Insulin-Like Growth Factor I | 2 | 2016 | 1929 | 0.350 |
Why?
|
Inheritance Patterns | 1 | 2012 | 340 | 0.350 |
Why?
|
Sex Characteristics | 3 | 2016 | 2633 | 0.350 |
Why?
|
Parathyroid Glands | 1 | 2012 | 518 | 0.340 |
Why?
|
Estrogen Receptor alpha | 1 | 2013 | 581 | 0.330 |
Why?
|
Norpregnenes | 1 | 2008 | 6 | 0.320 |
Why?
|
Estrogen Receptor Modulators | 1 | 2008 | 58 | 0.310 |
Why?
|
Probability | 1 | 2014 | 2476 | 0.310 |
Why?
|
Musculoskeletal Abnormalities | 1 | 2009 | 101 | 0.310 |
Why?
|
Female | 48 | 2024 | 391875 | 0.300 |
Why?
|
Estrogens | 1 | 2015 | 1519 | 0.300 |
Why?
|
Insulin Resistance | 2 | 2016 | 3956 | 0.290 |
Why?
|
Diabetes Insipidus, Nephrogenic | 1 | 2007 | 20 | 0.290 |
Why?
|
Anthropometry | 3 | 2011 | 1349 | 0.280 |
Why?
|
Sex Factors | 8 | 2021 | 10538 | 0.280 |
Why?
|
Endocrine System Diseases | 1 | 2009 | 249 | 0.280 |
Why?
|
Lithium Carbonate | 1 | 2007 | 179 | 0.270 |
Why?
|
Bone and Bones | 3 | 2012 | 2566 | 0.270 |
Why?
|
Aged | 25 | 2024 | 168840 | 0.260 |
Why?
|
Calcium, Dietary | 2 | 2009 | 529 | 0.260 |
Why?
|
Rickets | 1 | 2006 | 70 | 0.250 |
Why?
|
Hyperparathyroidism, Secondary | 1 | 2006 | 125 | 0.250 |
Why?
|
Male | 35 | 2022 | 360035 | 0.250 |
Why?
|
Adolescent Nutritional Physiological Phenomena | 1 | 2005 | 62 | 0.240 |
Why?
|
Hydroxycholecalciferols | 2 | 2020 | 44 | 0.240 |
Why?
|
Seasons | 2 | 2021 | 1518 | 0.240 |
Why?
|
Risk Assessment | 9 | 2019 | 23953 | 0.220 |
Why?
|
Accidental Falls | 2 | 2020 | 1066 | 0.220 |
Why?
|
Epilepsy | 2 | 2009 | 3286 | 0.210 |
Why?
|
Child Nutritional Physiological Phenomena | 1 | 2005 | 295 | 0.210 |
Why?
|
Kidney Calculi | 1 | 2007 | 463 | 0.210 |
Why?
|
Thinness | 1 | 2006 | 490 | 0.200 |
Why?
|
Bone Diseases | 1 | 2006 | 419 | 0.200 |
Why?
|
Life Style | 4 | 2011 | 3909 | 0.200 |
Why?
|
Diagnosis, Computer-Assisted | 3 | 2011 | 708 | 0.200 |
Why?
|
Calcium Citrate | 1 | 2021 | 8 | 0.200 |
Why?
|
Femur Neck | 4 | 2014 | 314 | 0.190 |
Why?
|
Premenopause | 2 | 2006 | 1039 | 0.190 |
Why?
|
Nutritional Status | 2 | 2021 | 1612 | 0.190 |
Why?
|
Child | 17 | 2020 | 80086 | 0.190 |
Why?
|
Quality of Life | 4 | 2024 | 13338 | 0.180 |
Why?
|
Down Syndrome | 1 | 2009 | 898 | 0.180 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2024 | 10180 | 0.180 |
Why?
|
Reference Values | 4 | 2018 | 4921 | 0.180 |
Why?
|
Organometallic Compounds | 1 | 2004 | 649 | 0.170 |
Why?
|
Adolescent | 16 | 2020 | 88196 | 0.170 |
Why?
|
Age Factors | 6 | 2024 | 18379 | 0.170 |
Why?
|
Albumins | 1 | 2022 | 575 | 0.170 |
Why?
|
United Arab Emirates | 1 | 2019 | 42 | 0.170 |
Why?
|
Thiophenes | 1 | 2004 | 569 | 0.170 |
Why?
|
Africa, Northern | 1 | 2019 | 86 | 0.160 |
Why?
|
Asymptomatic Diseases | 1 | 2022 | 587 | 0.160 |
Why?
|
Meta-Analysis as Topic | 2 | 2022 | 1376 | 0.160 |
Why?
|
Blood Pressure | 1 | 2015 | 8479 | 0.160 |
Why?
|
Densitometry | 1 | 2019 | 151 | 0.160 |
Why?
|
Neck Dissection | 1 | 2020 | 201 | 0.160 |
Why?
|
Hematologic Neoplasms | 1 | 2011 | 1890 | 0.160 |
Why?
|
Adult | 14 | 2024 | 220781 | 0.160 |
Why?
|
Saudi Arabia | 1 | 2019 | 210 | 0.160 |
Why?
|
Aging | 3 | 2023 | 8689 | 0.160 |
Why?
|
Aged, 80 and over | 11 | 2020 | 58859 | 0.160 |
Why?
|
Body Mass Index | 5 | 2021 | 12932 | 0.160 |
Why?
|
Decision Support Techniques | 1 | 2008 | 1998 | 0.150 |
Why?
|
Luminescence | 1 | 2018 | 108 | 0.150 |
Why?
|
Breast Neoplasms | 2 | 2024 | 20985 | 0.150 |
Why?
|
Femur | 3 | 2013 | 1308 | 0.150 |
Why?
|
Models, Theoretical | 1 | 2009 | 3576 | 0.140 |
Why?
|
Diet, Mediterranean | 1 | 2024 | 742 | 0.140 |
Why?
|
Vocal Cord Paralysis | 1 | 2020 | 272 | 0.140 |
Why?
|
Postmenopause | 3 | 2020 | 2513 | 0.140 |
Why?
|
Teriparatide | 1 | 2019 | 227 | 0.140 |
Why?
|
Validation Studies as Topic | 1 | 2017 | 162 | 0.140 |
Why?
|
Leptin | 1 | 2005 | 1593 | 0.140 |
Why?
|
Follow-Up Studies | 5 | 2021 | 39078 | 0.140 |
Why?
|
Administration, Oral | 1 | 2024 | 4010 | 0.130 |
Why?
|
Practice Guidelines as Topic | 2 | 2017 | 7380 | 0.130 |
Why?
|
Medical Records | 1 | 2002 | 1407 | 0.130 |
Why?
|
Chromatography, Liquid | 1 | 2020 | 983 | 0.130 |
Why?
|
Latin America | 1 | 2017 | 410 | 0.130 |
Why?
|
Automation | 1 | 2018 | 587 | 0.130 |
Why?
|
Guidelines as Topic | 2 | 2018 | 1385 | 0.130 |
Why?
|
North America | 2 | 2017 | 1275 | 0.130 |
Why?
|
Neck | 1 | 2020 | 735 | 0.130 |
Why?
|
Databases, Factual | 4 | 2020 | 7948 | 0.130 |
Why?
|
Asia | 1 | 2017 | 618 | 0.130 |
Why?
|
Social Class | 1 | 2004 | 2003 | 0.130 |
Why?
|
Calcium-Binding Proteins | 1 | 2020 | 1069 | 0.130 |
Why?
|
Hypopituitarism | 1 | 2017 | 250 | 0.130 |
Why?
|
Africa | 1 | 2017 | 709 | 0.120 |
Why?
|
Immunoassay | 1 | 2018 | 746 | 0.120 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2018 | 1540 | 0.120 |
Why?
|
Postoperative Complications | 3 | 2024 | 15627 | 0.120 |
Why?
|
Health Care Surveys | 1 | 2002 | 2425 | 0.120 |
Why?
|
Cross-Sectional Studies | 3 | 2023 | 26063 | 0.110 |
Why?
|
Europe | 2 | 2019 | 3419 | 0.110 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2013 | 15867 | 0.110 |
Why?
|
Cause of Death | 1 | 2024 | 3686 | 0.110 |
Why?
|
Tandem Mass Spectrometry | 1 | 2020 | 1183 | 0.110 |
Why?
|
Administration, Cutaneous | 1 | 2015 | 712 | 0.100 |
Why?
|
Calcium Gluconate | 1 | 2012 | 22 | 0.100 |
Why?
|
Human Growth Hormone | 1 | 2017 | 638 | 0.100 |
Why?
|
Femoral Fractures | 1 | 2016 | 375 | 0.100 |
Why?
|
Middle Aged | 14 | 2024 | 220382 | 0.100 |
Why?
|
Ultrasonography | 1 | 2005 | 5966 | 0.100 |
Why?
|
Societies, Medical | 4 | 2019 | 3904 | 0.090 |
Why?
|
Mass Spectrometry | 1 | 2018 | 2189 | 0.090 |
Why?
|
Nuclear Family | 1 | 2012 | 311 | 0.090 |
Why?
|
Risk Factors | 10 | 2017 | 74055 | 0.090 |
Why?
|
Qualitative Research | 1 | 2021 | 3008 | 0.090 |
Why?
|
Neoplasm Staging | 2 | 2024 | 11096 | 0.090 |
Why?
|
Diet Surveys | 2 | 2024 | 1162 | 0.090 |
Why?
|
Evidence-Based Medicine | 1 | 2022 | 3685 | 0.090 |
Why?
|
Incidence | 2 | 2019 | 21322 | 0.090 |
Why?
|
Imidazoles | 1 | 2016 | 1179 | 0.080 |
Why?
|
Reproducibility of Results | 4 | 2024 | 20078 | 0.080 |
Why?
|
Energy Metabolism | 1 | 2020 | 2875 | 0.080 |
Why?
|
Demography | 1 | 2014 | 1648 | 0.080 |
Why?
|
Lumbar Vertebrae | 2 | 2011 | 1872 | 0.080 |
Why?
|
Multivariate Analysis | 3 | 2008 | 12054 | 0.080 |
Why?
|
Prognosis | 3 | 2024 | 29551 | 0.080 |
Why?
|
Treatment Outcome | 6 | 2024 | 64591 | 0.080 |
Why?
|
Research Design | 2 | 2021 | 6168 | 0.080 |
Why?
|
Ventricular Function, Right | 1 | 2012 | 618 | 0.070 |
Why?
|
Heart Failure | 1 | 2012 | 11653 | 0.070 |
Why?
|
Health Policy | 1 | 2019 | 2680 | 0.070 |
Why?
|
Myocardial Contraction | 1 | 2012 | 1516 | 0.070 |
Why?
|
Osteitis Fibrosa Cystica | 1 | 2006 | 11 | 0.070 |
Why?
|
Logistic Models | 2 | 2013 | 13240 | 0.070 |
Why?
|
Solar System | 1 | 2005 | 12 | 0.070 |
Why?
|
Thyroidectomy | 1 | 2012 | 907 | 0.070 |
Why?
|
Epidemiologic Methods | 1 | 2011 | 1336 | 0.070 |
Why?
|
Genotype | 2 | 2013 | 12976 | 0.060 |
Why?
|
Thalassemia | 1 | 2006 | 268 | 0.060 |
Why?
|
Mediterranean Region | 1 | 2005 | 47 | 0.060 |
Why?
|
Linear Models | 2 | 2006 | 5865 | 0.060 |
Why?
|
Etidronic Acid | 1 | 2004 | 63 | 0.060 |
Why?
|
World Health Organization | 2 | 2008 | 1315 | 0.060 |
Why?
|
Methotrexate | 1 | 2011 | 1720 | 0.060 |
Why?
|
Body Weights and Measures | 1 | 2004 | 208 | 0.060 |
Why?
|
Polymerase Chain Reaction | 1 | 2013 | 6086 | 0.060 |
Why?
|
Patient Selection | 2 | 2009 | 4240 | 0.060 |
Why?
|
Receptors, Calcitriol | 1 | 2006 | 360 | 0.060 |
Why?
|
Dexamethasone | 1 | 2011 | 1944 | 0.050 |
Why?
|
Diet Records | 1 | 2005 | 427 | 0.050 |
Why?
|
Nutritional Requirements | 1 | 2005 | 275 | 0.050 |
Why?
|
Membrane Proteins | 1 | 2020 | 7849 | 0.050 |
Why?
|
Mass Screening | 1 | 2019 | 5424 | 0.050 |
Why?
|
Child, Preschool | 2 | 2020 | 42209 | 0.050 |
Why?
|
Long-Term Care | 1 | 2007 | 633 | 0.050 |
Why?
|
Prevalence | 1 | 2020 | 15698 | 0.050 |
Why?
|
Hand Strength | 1 | 2005 | 456 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3080 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3200 | 0.050 |
Why?
|
Recombinant Proteins | 1 | 2012 | 6525 | 0.050 |
Why?
|
Cohort Studies | 3 | 2024 | 41366 | 0.050 |
Why?
|
Comorbidity | 1 | 2016 | 10494 | 0.050 |
Why?
|
Radius | 1 | 2004 | 440 | 0.050 |
Why?
|
Mothers | 1 | 2012 | 2191 | 0.050 |
Why?
|
Glucocorticoids | 1 | 2011 | 2163 | 0.050 |
Why?
|
Disease Notification | 1 | 2002 | 95 | 0.050 |
Why?
|
Calcium Channel Blockers | 1 | 2004 | 694 | 0.050 |
Why?
|
Survival Analysis | 1 | 2014 | 10075 | 0.050 |
Why?
|
Physicians | 1 | 2019 | 4586 | 0.050 |
Why?
|
Nutrition Assessment | 1 | 2024 | 728 | 0.050 |
Why?
|
Nutrition Policy | 1 | 2005 | 471 | 0.050 |
Why?
|
Case-Control Studies | 2 | 2009 | 22097 | 0.040 |
Why?
|
Young Adult | 3 | 2024 | 59068 | 0.040 |
Why?
|
Fractures, Spontaneous | 1 | 2002 | 231 | 0.040 |
Why?
|
Spine | 1 | 2007 | 1118 | 0.040 |
Why?
|
Models, Statistical | 2 | 2011 | 5078 | 0.040 |
Why?
|
Androgen Antagonists | 1 | 2008 | 1407 | 0.040 |
Why?
|
Injections, Intravenous | 1 | 2002 | 1379 | 0.040 |
Why?
|
Placebos | 1 | 2004 | 1661 | 0.040 |
Why?
|
Hormones | 1 | 2023 | 867 | 0.040 |
Why?
|
Echocardiography | 1 | 2012 | 4981 | 0.040 |
Why?
|
Recurrence | 1 | 2012 | 8466 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2023 | 12127 | 0.040 |
Why?
|
Ventricular Function, Left | 1 | 2012 | 3876 | 0.040 |
Why?
|
Middle East | 1 | 2019 | 231 | 0.040 |
Why?
|
Stroke Volume | 1 | 2012 | 5487 | 0.040 |
Why?
|
Developing Countries | 1 | 2010 | 2882 | 0.040 |
Why?
|
Urban Population | 1 | 2006 | 2032 | 0.040 |
Why?
|
Infant | 1 | 2020 | 36183 | 0.040 |
Why?
|
Algorithms | 1 | 2017 | 14002 | 0.030 |
Why?
|
Thyroid Gland | 1 | 2023 | 1168 | 0.030 |
Why?
|
Collagen | 1 | 2005 | 2637 | 0.030 |
Why?
|
Regression Analysis | 1 | 2005 | 6340 | 0.030 |
Why?
|
Time Factors | 1 | 2017 | 39947 | 0.030 |
Why?
|
Hypertension | 1 | 2015 | 8527 | 0.030 |
Why?
|
Age Determination by Skeleton | 1 | 2014 | 126 | 0.030 |
Why?
|
Disease-Free Survival | 1 | 2024 | 6813 | 0.030 |
Why?
|
Kidney Failure, Chronic | 1 | 2006 | 2462 | 0.030 |
Why?
|
Terminology as Topic | 2 | 2014 | 1534 | 0.030 |
Why?
|
Consensus | 1 | 2023 | 3115 | 0.030 |
Why?
|
Retrospective Studies | 3 | 2009 | 80430 | 0.030 |
Why?
|
Adipose Tissue | 1 | 2004 | 3306 | 0.030 |
Why?
|
Animals | 2 | 2020 | 168253 | 0.020 |
Why?
|
Hormone Replacement Therapy | 1 | 2017 | 751 | 0.020 |
Why?
|
Advisory Committees | 1 | 2016 | 783 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2005 | 7817 | 0.020 |
Why?
|
Calcinosis | 1 | 2019 | 1469 | 0.020 |
Why?
|
Exercise | 1 | 2005 | 5874 | 0.020 |
Why?
|
Schizophrenia | 1 | 2007 | 6927 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2004 | 7996 | 0.020 |
Why?
|
Body Height | 1 | 2014 | 1570 | 0.020 |
Why?
|
Documentation | 1 | 2014 | 895 | 0.020 |
Why?
|
Diet | 1 | 2024 | 8058 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2024 | 9267 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2006 | 20551 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8623 | 0.010 |
Why?
|
Radiography | 1 | 2011 | 6963 | 0.010 |
Why?
|
Prospective Studies | 1 | 2024 | 54339 | 0.010 |
Why?
|
Pediatrics | 1 | 2014 | 3593 | 0.010 |
Why?
|
United States | 1 | 2002 | 72202 | 0.010 |
Why?
|
Risk | 1 | 2004 | 9605 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2004 | 12429 | 0.010 |
Why?
|